[8-K] AMES NATIONAL CORP Reports Material Event

Rhea-AI Filing Summary

Ames National Corporation filed an 8-K to announce it furnished a news release with financial results for the three and nine months ended September 30, 2025. The disclosure was made under Item 2.02: Results of Operations and Financial Condition, with the full news release provided as Exhibit 99.1. The company’s common stock trades on the NASDAQ Capital Market under the symbol ATLO.

false 0001132651 0001132651 2025-10-17 2025-10-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 17, 2025

Date of Report (Date of Earliest Event Reported)

AMES NATIONAL CORPORATION
(Exact Name of Registrant as Specified in its Charter)

Iowa	0-32637	42-1039071
(State or Other Jurisdiction of  Incorporation or Organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

323 Sixth Street

Ames, Iowa 50010

(Address of Principal Executive Offices) (Zip Code)

(515) 232-6251

NOT APPLICABLE

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock	ATLO	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On October 17, 2025, Ames National Corporation issued a News Release announcing financial results for the three and nine months ended September 30, 2025. A copy of the News Release is furnished as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

	Exhibit No.		Description
	99.1		News Release dated October 17, 2025
	104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMES NATIONAL CORPORATION
Date: October 17, 2025	By:	/s/ John P. Nelson
		John P. Nelson, Chief Executive Officer and President
		Principal Executive Officer

FAQ

What did ATLO disclose in this 8-K filing?

Ames National Corporation furnished a news release announcing financial results for the three and nine months ended September 30, 2025 under Item 2.02.

Which period does ATLO’s update cover?

The news release covers financial results for the three and nine months ended September 30, 2025.

Where can I find ATLO’s detailed results?

The full results are in the news release furnished as Exhibit 99.1 to the 8-K.

What is ATLO’s stock symbol and exchange?

ATLO trades on the NASDAQ Capital Market.

Which 8-K item did ATLO use for this disclosure?

Item 2.02: Results of Operations and Financial Condition.

When was the news release issued?

October 17, 2025, as indicated by the exhibit description.

What other exhibit is listed in the filing?

Exhibit 104: Cover Page Interactive Data File (embedded within the Inline XBRL document).